Tuberculosis
Tuberculosis (TB), caused by the bacteria Mycobacterium tuberculosis, primarily affects the lungs and can present as either latent or active disease. Active TB is characterized by symptoms such as a bloody cough, fever, night sweats, weight loss, and fatigue, while latent TB shows no symptoms but can progress to an active, potentially lethal condition.
Health Outcomes
- Adverse Safety Concern from Antimicrobial Resistance
- Altered Antibiotic Susceptibility
- Altered Innate Immune Response
- Asymptomatic Carrier Status
- Co-Aggregation with Pathogens
- Decreased Granulocyte Count in Lungs
- Diagnosis of Meningitis
- Elevated Serum IFN-γ Levels
- Enhanced Anti-Infective Properties
- Enhanced Antimicrobial Capacity
- Enhanced Antimicrobial Resistance
- Enhanced Antipathogenic Activity
- Enhanced Bactericidal Activity
- Enhanced Disease Resistance
- Enhanced Host Resistance
- Enhanced IFN-γ Production
- Enhanced Immune Capacity
- Enhanced Immune Evasion
- Enhanced Immune Function Post-Intervention
- Enhanced Immune Response Against Specific Bacteria
- Enhanced Immune System Function
- Enhanced Innate Immune Cell Activity
- Enhanced Interferon Gamma Production
- Enhanced Interferon Production
- Enhanced Phagocytic Capacity of Leukocytes
- Enhanced Phagocytic Capacity of Mononuclear Phagocytes
- Enhanced Phagocytosis by Monocyte-Derived Dendritic Cells
- Enhanced Protection Against Infection
- Enhanced Pulmonary Immune Response
- Enhanced Resistance to Bacterial Infections
- Enhanced Resistance to Infections
- Enhanced Respiratory Burst Activity
- Improved Acquired Immunity
- Improved Anti-infection Response
- Improved Antibacterial Activity
- Improved Antibiotic Resistance Outcomes
- Improved Antibiotic Susceptibility
- Improved Antimicrobial Production
- Improved Bacterial Survival Rate
- Improved Bacterial Viability Under Stress
- Improved Bactericidal Function of Phagocytic Cells
- Improved Chest X-Ray Finding
- Improved Cure Rate
- Improved Delayed-Type Hypersensitivity Response
- Improved Health in HIV-Positive Subjects
- Improved Histopathological Findings in Lungs
- Improved Host Health
- Improved Host Immunity
- Improved IFN-γ Levels
- Improved Immune Activation
- Improved Immune Cell Counts
- Improved Immune Function
- Improved Immune Homeostasis
- Improved Immune Response
- Improved Immune System Activity
- Improved Immunological Biomarkers
- Improved Immunological Indices
- Improved Immunological Response
- Improved Infection Protection
- Improved Innate Immunity
- Improved Lower Limit of Detection
- Improved Microbial Identification
- Improved Neutrophil Function
- Improved Overall Survival During Infection
- Improved Pathogen Clearance
- Improved Pathogen Tolerance
- Improved Phagocyte-mediated Bactericidal Activity
- Improved Phagocytic Activity of Granulocytes
- Improved Phagocytosis
- Improved Relative Survival Rate Against Pathogen
- Improved Resistance against Infections
- Improved Resistance to Chronic Infections
- Improved Resistance to Infections
- Improved Resistance to Pathogenic Infection
- Improved Serum-Mediated Pathogen Killing
- Improved Survival Rate Against Infection
- Improved Survival Rate Following Infection
- Improved Systemic Immunity
- Improved Total Antibody Concentration
- Improved Vaccine-Specific IgG Levels
- Incidence of Death
- Increased Anti-Apoptotic Response Against Bacterial Infection
- Increased Antibacterial Compound Production
- Increased Antibody Response
- Increased Antimicrobial Resistance
- Increased Body Temperature
- Increased CD3+CD4+ Cell Counts
- Increased CD3+CD4+IFN-γ+ T Cell Count
- Increased CD3+CD8+ Cell Counts
- Increased CD8+ T Cells
- Increased Effectiveness Against Antibiotic-Resistant Bacteria
- Increased Fever
- Increased IFN-γ Concentration
- Increased Immune Function
- Increased Infection
- Increased Inhibition of Pathogenic Bacteria
- Increased Interferon Production
- Increased Interferon-Gamma Levels
- Increased LL-37 Levels
- Increased Leukocyte Count
- Increased Natural Killer T Cells
- Increased Opsonophagocytic Activity
- Increased PMN Cell Phagocytic Capacity
- Increased Pathogen Resistance
- Increased Phagocytic Index
- Increased Post-Infection Lung Monocyte Levels
- Increased Serum Interferon Gamma Levels
- Increased Specific Antibody Levels
- Increased Survival Against Pathogens
- Increased Survival During Pathogenic Exposure
- Increased Survival Rates of Infected Hosts
- Increased T Cell Count
- Increased Vaccine-Specific Plasma Immunoglobulin G (IgG)
- Induction of Antimicrobial Chemokines
- Induction of Th1 Immune Response
- Inhibited Pathogenic Microbes
- Inhibition of Harmful Bacterial Growth
- Maintained Antibiotic Susceptibility
- No Significant Change in BCG Phagocytic Intake
- Potentially Effective Antibacterial Proteins
- Protection Against Cellular Damage Induced by Pathogens
- Protection Against Pathogen Dissemination
- Reduced Anti-Tuberculosis Drug Induced Liver Injury
- Reduced Antibiotic Sensitivity
- Reduced Apoptosis Induced by Pathogens
- Reduced Appetite
- Reduced Appetite Changes
- Reduced BCG Phagocytic Intake
- Reduced Bacterial Culturability
- Reduced Bacterial Infection Severity
- Reduced Bacterial Load
- Reduced Bacterial Load in Blood
- Reduced Bacterial Load in Lungs
- Reduced CD4+ T Cell Count in Draining Lymph Nodes
- Reduced Cervical Lymphadenopathy Symptom
- Reduced Cervical Lymphadenopathy Symptoms
- Reduced Circulating Monocytes
- Reduced Cytokine Secretion in Dendritic Cells
- Reduced Duration of Infectious Diseases
- Reduced Growth Decline After Infection
- Reduced Harmful Bacterial Populations
- Reduced Household Transmission Rate
- Reduced Immune Cell Proliferation
- Reduced Incidence of Bacterial Infections
- Reduced Incidence of Common Infectious Diseases
- Reduced Incidence of Invasive Infections
- Reduced Induced Innate Immune Response
- Reduced Infection Incidence
- Reduced Infection Rate
- Reduced Infection Severity
- Reduced Interferon-Gamma Levels
- Reduced Interferon-Gamma Production
- Reduced M1 Macrophage Population
- Reduced Mortality Post-Infection
- Reduced Mortality Rate Before Discharge
- Reduced Mortality Rate During Pathogen Challenge
- Reduced Mycobacterium bovis BCG Phagocytic Uptake
- Reduced NO Secretion Induced by LPS
- Reduced Nontransferable Antibiotic Resistance
- Reduced Pathogen Activity
- Reduced Pathogen Counts in Organs
- Reduced Pathogen Excretion
- Reduced Pathogen Growth
- Reduced Pathogen Incidence
- Reduced Pathogen Infection
- Reduced Pathogen Resistance
- Reduced Pathogen Viability
- Reduced Pathogen-Induced Weight Loss
- Reduced Pathogenic Bacteria
- Reduced Pathogenic Bacterial Load In Vivo
- Reduced Pathogenic Bacterial Populations
- Reduced Pathogenic Load
- Reduced Phagocytic Activity
- Reduced Pulmonary Inflammation
- Reduced Respiratory Burst Activity
- Reduced Respiratory Pathogen Load
- Reduced Risk of Infection
- Reduced Risk of Pathogen Dissemination
- Reduced Risk of Prolonged Respiratory Infections
- Reduced Susceptibility to Infection
- Reduced T-Effector Memory Cell Activity
- Reduced Total Infections
- Reduced Transmission of Antibiotic-Resistant Genes
- Reduced Treatment Failure
- Reduced Treatment Failure Rate
- Reduced Virulence of Pathogens
- Reduced Virulence or Safety Concerns
- Restored Immunological Function in Immunosuppressed Mice
- Restored T-Cell Population
- Stable Antibiotic Susceptibility Profiles
- Strain Authentication and Identification
- Suppressed Pathogenic Growth
- Sustained Immune Function
- Synergistic Antibiotic Effect
- White Blood Cell Count